Diabetes
| T2D & Obesity
Diabetes
T2D & Obesity

Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Trial Results

book_2 Source: ADA 2023 - Symposium 
calendar_today Published on Medfyle: July 2023
import_contacts 7 min
headphones 7 min

In this medfyle

Two phase II studies showed that the triple agonist retatrutide is associated with significant weight loss in obese patients and substantial improvement in glycemia control and significant weight loss in patients with T2D.

Expert commentary

Christos S. Mantzoros, MD, DSc, PhD

Harvard Medical School,
Boston, MA, USA.

About this Medfyle
Read more arrow_downward Hide arrow_upward

This content is intended for an international audience of non-UK healthcare professionals. The content is made available through a licensing agreement between Infomedica and the American Diabetes Association (ADA).

The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the ADA.

©2023 Infomedica-Medfyle. All rights reserved.

MedfyleToday | Day 4

Feedback